Eroglu, Z., Mehnert, J. M., Giobbie-Hurder, A., Kendra, K. L., In, G. K., Salama, A. K. S., … Sullivan, R. J. (2023). Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Eroglu, Zeynep, Janice M. Mehnert, Anita Giobbie-Hurder, Kari Lynn Kendra, Gino Kim In, April K. S. Salama, Gary C. Doolittle, et al. “Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Eroglu Z, Mehnert JM, Giobbie-Hurder A, Kendra KL, In GK, Salama AKS, et al. Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Eroglu, Zeynep, et al. “Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Eroglu Z, Mehnert JM, Giobbie-Hurder A, Kendra KL, In GK, Salama AKS, Doolittle GC, Sosman JA, Valerin JB, Medina TM, Lutzky J, Moschos SJ, Khushalani NI, Markowitz J, Takebe N, Chen HX, Knight LW, Davies MA, Sullivan RJ. Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466). JOURNAL OF CLINICAL ONCOLOGY. 2023.